These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2167306)

  • 21. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
    Declerck PJ; De Mol M; Vaughan DE; Collen D
    J Biol Chem; 1992 Jun; 267(17):11693-6. PubMed ID: 1601844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells.
    Wojta J; Nakamura T; Fabry A; Hufnagl P; Beckmann R; McGrath K; Binder BR
    Blood; 1994 Jul; 84(1):151-7. PubMed ID: 7517205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells.
    Grobmyer SR; Kuo A; Orishimo M; Okada SS; Cines DB; Barnathan ES
    J Biol Chem; 1993 Jun; 268(18):13291-300. PubMed ID: 7685759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator.
    Bartha K; Declerck PJ; Moreau H; Nelles L; Collen D
    J Biol Chem; 1991 Jan; 266(2):792-7. PubMed ID: 1898737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
    Hajjar KA; Hamel NM
    J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.
    Hajjar KA; Reynolds CM
    J Clin Invest; 1994 Feb; 93(2):703-10. PubMed ID: 8113404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Collen D
    J Biol Chem; 1991 Mar; 266(7):4041-4. PubMed ID: 1900284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
    Lee JA; Croucher DR; Ranson M
    Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
    J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
    Reilly CF; Hutzelmann JE
    J Biol Chem; 1992 Aug; 267(24):17128-35. PubMed ID: 1512250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
    Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells.
    Mulder M; Kohnert U; Fischer S; van Hinsbergh VW; Verheijen JH
    Blood Coagul Fibrinolysis; 1997 Mar; 8(2):124-33. PubMed ID: 9518044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes.
    Simon DI; Xu H; Vaughan DE
    Biochim Biophys Acta; 1995 Aug; 1268(2):143-51. PubMed ID: 7662701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
    Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
    Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
    Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
    Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.